Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
Castrate-Resistant Prostate Cancer
DRUG: ISIS EIF4E Rx|DRUG: ISIS EIF4E Rx|DRUG: ISIS EIF4E Rx|DRUG: Prednisone|DRUG: Docetaxel
Progression free survival, At the end of each 21 day cycle
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.